Last reviewed · How we verify

Meningitis due to Bacteroides — Treatment Landscape & Competitive Intelligence

Meningitis due to Bacteroides (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Meningitis due to Bacteroides, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Metro I.V. In Plastic Container METRONIDAZOLE Baxter Nitroimidazole Antimicrobial [EPC] 1963-01-01
Metronidazol Metronidazol University of Oslo Thioredoxin reductase

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Baxter · 1 drug in Meningitis due to Bacteroides
  2. University of Oslo · 1 drug in Meningitis due to Bacteroides

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Meningitis due to Bacteroides:

Cite this brief

Drug Landscape (2026). Meningitis due to Bacteroides — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/meningitis-due-to-bacteroides. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing